Needle-based Percutaneous Ablation of Liver Tumors.

The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1. Using a needle under image guidance, the liver tumor is accessed and INT001 is injected. Upon injection into tumor, does INT001 ablate/kill the tumor entirely? 2. What medical problems do participants experience when receiving INT001? Participants will: Receive INT001 on day 1. Visit the clinic day 7, 30 and 90. Receive lab tests during each visit and MRI on day 30 and 90.

NCT Number	NCT06689670
Lead Sponsor	inTumo Therapeutics, Inc.
Conditions	Liver Tumors, HCC - Hepatocellular Carcinoma, Metastatic Liver Tumor
Enrollment	31 participants
Start Date	2024-10-28
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-20